Component
Human circulating soluble VCAM-1 concentration
Human circulating soluble VCAM-1 concentration. Interpret through the linked experimental species, preparation, compartment and exposure; no universal causal effect is implied.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
The 12-week purified berry anthocyanin trial reported lower circulating soluble VCAM-1 versus placebo.
Experimental context and source evidence
- evidence_access
- Primary indexed abstract reviewed; full methods, figures, exact doses or endpoint-specific species assignments may remain unextracted.
- experimental_contrast
- {"intervention": "320 mg/day purified berry anthocyanin mixture", "comparator": "Placebo for 12 weeks", "endpoint": "The 12-week purified berry anthocyanin trial reported lower circulating soluble VCAM-1 versus placebo.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
- experimental_model
- 150 hypercholesterolemic participants; 320 mg/day berry-isolated anthocyanins for 12 weeks, placebo-controlled.
- interpretation_status
- Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
- limitations
- Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
- plain_language
- The 12-week purified berry anthocyanin trial reported lower circulating soluble VCAM-1 versus placebo.
- primary_references
- Purified anthocyanin supplementation improves endothelial function via NO-cGMP activation in hypercholesterolemic individuals. | 2011 | DOI 10.1373/clinchem.2011.167361 | PMID 21926181 | https://pubmed.ncbi.nlm.nih.gov/21926181/ | https://doi.org/10.1373/clinchem.2011.167361
- source_locator
- Reviewed reference lines 52-52; exact primary location described in quoted passage where extracted.
Anthocyanins: detailed mechanisms of action (reviewed 4 October 2026) · lines 52–52
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · 150 hypercholesterolemic participants; 320 mg/day berry-isolated anthocyanins for 12 weeks, placebo-controlled. · source_derived_draft · unverified_draft
**Purified berry anthocyanins changed human vascular function.** A 2011 study included a 12-person acute crossover and a 150-person, 12-week trial of 320 mg/day. Flow-mediated dilation (FMD) and plasma cGMP improved; LDL cholesterol and soluble VCAM-1 decreased, with HDL cholesterol increasing. Additional inhibitor experiments in six people and rat aortic rings supported involvement of NO–cGMP signaling. The accessible abstract does not identify every inhibitor or its route, so this reference does not invent those details. FMD is vascular physiology, not proof of a particular parent molecule binding eNOS or prevention of cardiovascular events. [Zhu et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21926181/).
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.